Podcasts about Bain Capital

Welcome back to the Alt Goes Mainstream podcast.Today's episode is with the CIO of an insurance company responsible for more than $300B in assets and a major focus on private markets.Lincoln Financial EVP and CIO Jayson Bronchetti and I sat down recently at Lincon Financial's headquarters in Radnor, Pennsylvania to discuss the increasing involvement of insurance companies in private markets.Jayson, who is a member of Lincoln Financial's Senior Management Committee and serves as the primary investment officer to Lincoln's Board of Directors on all investment-related matters, is responsible for more than $300B in assets across the general account portfolio and the separate account mutual fund complex. He's also chairman of the board of directors of the Lincoln Variable Insurance Product Trust family of over 100 mutual funds. He's also on the board of the Lincoln Financial Foundation.Fresh off recent partnerships with Bain Capital and Partners Group on private markets investment products and Bain Capital taking a stake in Lincoln's business, Jayson and I had a fascinating conversation about how insurance companies can approach private markets and how they can build unique and differentiated partnerships with asset managers.We discussed:The evolving role of insurance companies as LPs in private markets.Why asset and liability matching is a critical framework to allocating to private markets.How the general account of an insurance company creates interesting opportunities for strategic relationships and partnerships with alternative asset managers.The benefit of having a business that works with financial advisors and individuals.The importance of educating wholesalers about private markets – and why insurance wholesalers might have an advantage in educating advisors and clients about private markets products and strategies.Thanks Jayson for coming on the show to share your wisdom and expertise about private markets and insurance.Subscribe to Alt Goes Mainstream to receive the weekly newsletter every Sunday and all of AGM's podcasts.A word from AGM podcast sponsor, Ultimus Fund SolutionsThis episode of Alt Goes Mainstream is brought to you by Ultimus Fund Solutions, a leading full-service fund administrator for asset managers in private and public markets. As private markets continue to move into the mainstream, the industry requires infrastructure solutions that help funds and investors keep pace. In an increasingly sophisticated financial marketplace, investment managers must navigate a growing array of challenges: elaborate fund structures, specialized strategies, evolving compliance requirements, a growing need for sophisticated reporting, and intensifying demands for transparency.To assist with these challenging opportunities, more and more fund sponsors and asset managers are turning to Ultimus, a leading service provider that blends high tech and high touch in unique and customized fund administration and middle office solutions for a diverse and growing universe of over 450 clients and 1,800 funds, representing $500 billion assets under administration, all handled by a team of over 1,000 professionals. Ultimus offers a wide range of capabilities across registered funds, private funds and public plans, as well as outsourced middle office services. Delivering operational excellence, Ultimus helps firms manage the ever-changing regulatory environment while meeting the needs of their institutional and retail investors. Ultimus provides comprehensive operational support and fund governance services to help managers successfully launch retail alternative products.Visit www.ultimusfundsolutions.com to learn more about Ultimus' technology enhanced services and solutions or contact Ultimus Executive Vice President of Business Development Gary Harris on email at gharris@ultimusfundsolutions.com.We thank Ultimus for their support of alts going mainstream.Show Notes00:40 Introduction to Jayson Bronchetti02:20 Sponsor Message: Ultimus Fund Solutions03:37 Welcome to the Podcast04:03 Jayson's Background in Private Markets04:57 Evolution of Insurance Companies in Private Markets06:37 Symbiotic Relationship Between GPs and Insurers08:40 Understanding Liquidity and Illiquidity11:19 Diligencing Private Markets Managers13:25 Balancing Scale and Performance14:09 Boots on the Ground: Sourcing Edge14:42 Evolution of Alternative Asset Managers14:53 Lincoln's Unique Position in the Market19:32 Strategic Partnerships with Bain and Partners Group20:03 The Value of Distribution Relationships22:14 The Democratization of Alternative Investments22:49 The Intersection of Private Markets, Wealth, and Insurance23:10 Approaching Private Markets with the General Account24:18 Launching Strategies with Bain and Partners Group24:50 Incubating New Strategies for Retail Consumers25:16 Building a Customized Investment Strategy25:45 Designing Purposeful Investment Funds26:00 Ensuring Accessibility and Proper Wrappers26:08 Liquidity and Product Matching26:15 Seeding Strategies with the General Account26:58 One Lincoln Approach27:12 Finding Opportunities in the Seams27:46 Balancing General Account and Distribution Needs28:07 Product Innovation in the Wealth Channel28:53 Healthy Tension in Product Design31:51 Importance of Asset Liability Management33:05 Educating the Distribution Team34:47 Training Modules for Wholesalers36:28 Boots on the Ground: The Power of Relationships37:45 Simplifying Complex Products40:44 Democratizing Alternative Investments41:10 Straddling Institutional and Individual Mindsets41:35 Integrating Private Markets into Retirement Products43:13 Future of Private Markets in Retirement Portfolios43:57 Product Innovation and Technology45:15 Private Markets in Insurance Products47:16 Focus on Private Credit49:38 Risks in Private Credit50:29 Excitement for the Future of Private Markets51:01 Conclusion and Final Thoughts Disclosure from Lincoln Financial Registration statements for each of the evergreen funds have been filed with the Securities and Exchange Commission and are available from the EDGAR database on the SEC's website (www.sec.gov). The information in the registration statements is not complete and may be changed. The securities of neither fund may be sold until its registration statement is effective. An investor should consider the investment objectives, risks, charges and expenses of each fund carefully before investing. This and other information about each fund will be contained in the fund's final prospectus, which investors should read carefully when available from t...

Wanna learn how to comply with PFAS Removal targets with the lowest risk and without breaking the bank? Listen to this!More #water insights? Connect with me on Linkedin: https://www.linkedin.com/in/antoinewalter1/

In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.

In this episode of Capital for Good we speak with Greg Shell, a seasoned investor, civic leader, and partner at Goldman Sachs Alternatives, where he leads the firm's inclusive growth strategy. Over the course of the conversation, we discuss how Shell's three decades and expertise in investing, and his commitments to creating opportunity and greater economic and social mobility, for many years pursued through board leadership and community and nonprofit engagement, have come together in impact investing, first at Bain Capital, and now at Goldman Sachs Alternatives.  Shell explains that he believes deeply in the power of capitalism — the power of the profit model to drive innovation, opportunities for ownership and wealth building, economic growth — and that the current system is failing to deliver broad based economic and social mobility. He notes that stagnant wages, growing income and wealth inequality, and deep and real economic insecurity, are all profound challenges, but ones that must and can be addressed.  “Our economy would be bigger and faster growing if more people could participate and contribute fully,” Shell says. This is also the thesis of the private equity strategy he leads at Goldman Sachs Alternatives that invests into affordable and high-quality health care, education and workforce development, and financial inclusion. In each vertical, Shell's team identifies companies that focus on remedying exclusion as social and economic challenge and market opportunity, where need drives demand, innovation expands access, and both lead to social impact and strong business fundamentals. We walk through two portfolio examples in education (online literacy intervention) and health care (autism services).  Despite the turbulence of the current environment, Shell is optimistic. “Human capital is the first, best and greatest asset we have,” he says. “Investing in human capital is always the right decision, and if we do it the right way” can deliver extraordinary returns, on every dimension. Thanks for Listening! Subscribe to Capital for Good on Apple, Amazon, Google, Spotify, or wherever you get your podcasts. Drop us a line at socialenterprise@gsb.columbia.edu.  Mentioned in this Episode Goldman Sachs Inclusive Growth 

Gaming giant Aristocrat Leisure brought in a rise in profit, but the market was unimpressed by what it heard. MARKET WRAP: ASX200: up 0.13% to 8,279 GOLD: $3,254 US/oz BITCOIN: $159,417 AUD The Energy sector was the strongest with Brent crude back over $66 US a barrel. Woodside Energy were beneficiaries, up 3.4%, Life360 rose another 9.5% after its earnings yesterday. Up over 1% were Wesfarmers, REA Group and Brambles Aristocrat Leisure reported growth in revenue of 9% and a 6% lift in profit. Shares closed 8.9% lower to $62.10. Bain Capital withdrew its bid for Insignia Financial, seeing the wealth management company fall 15.8% to $3.37. CSL, Goodman Group and Transurban all down. CURRENCY UPDATE: AUD/USD: 65.0 US cents AUD/GBP: 48.7 pence AUD/EUR: 57 Euro cents AUD/JPY: 95 Japanese yen AUD/NZD: 1.09 NZ dollars See omnystudio.com/listener for privacy information.

Ponemos el foco en las compañías europeas Infineon, Unicredit, Iveco Defense, Indra, Leonardo, Rheinmetall, Bain Capital y ST Micro. Con Pablo García, director general de Divacons Alphavalue.

Ponemos el foco en las compañías europeas Infineon, Unicredit, Iveco Defense, Indra, Leonardo, Rheinmetall, Bain Capital y ST Micro. Con Pablo García, director general de Divacons Alphavalue.

“We want to bring health care to a place where claims are processed in real-time, like checking out on Amazon,” says Stephen Krupa, CEO of HealthEdge. Krupa joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how HealthEdge’s core platform powers claims processing for more than 110 million people. He shares how legacy infrastructure still dominates (with 60% of health plans still relying on decades-old technology), why automation and gen AI will drive touchless transactions and how payer platforms must evolve to support member-centric care. Krupa also reflects on HealthEdge’s journey from startup to its transformation under Blackstone, and what the next chapter might look like with Bain Capital.See omnystudio.com/listener for privacy information.

Startups increasingly depend on mergers and acquisitions for exits due to a sluggish IPO market. Private equity firms have invested over $56 billion in acquiring private, venture-backed companies in the past five years. In 2023, private equity firms announced 22 acquisitions of seed- or venture-funded private companies, with three deals revealing a total of $8.3 billion. Notable recent transactions include ModMed's $5.3 billion sale to Clearlake Capital Group and HealthEdge's $2.6 billion acquisition by Bain Capital. Private equity firms prefer to buy established companies with substantial revenue, often resulting in acquisitions of mature startups. Seed-stage companies are less likely to attract private equity interest, as they face more favorable exit opportunities from strategic industry buyers. Although public PE firm valuations have declined, significant numbers of later-stage companies, with 789 private, venture-backed firms in the U.S. valued over $1 billion, present opportunities for acquisitions. Many of these firms have seen reduced valuations since their market peak four years ago, making them attractive for private equity acquisitions.Learn more on this news visit us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in​. In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing​, while Melanie shares the “seventh-grade brain report” that launched her career and why today's biomarker and platform-trial advances finally make true progress possible​. They break down: Why capital markets—not philanthropy alone—must fund $10-$50 M clinical trials ​ The business case that's luring big pharma back to neuro (“the decade of neurodegeneration”) ​ How a cystic-fibrosis-style royalty model could recycle billions into ALS research ​ The audacious goal to “put ourselves out of business” by making effective therapies commonplace ​ If you're curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat. SPONSORS: ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim's voice. ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode. SOCIAL: Website: https://tgnlu.com   Twitter: https://twitter.com/nlutimgreen   Facebook: https://www.facebook.com/NLUpod  Instagram: https://www.instagram.com/nlupod/  AUDIO ONLY: Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa  Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890   PERSONAL:  Tackle ALS: https://www.tackleals.com   Tim Green Books: https://authortimgreen.com Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of the Debtwired! podcast, Michael Ewald, Bain Capital's global head of private credit, joins Melina Chalkia, Debtwire's primary market reporter for North America, to unpack how one of the biggest players in the space is navigating a volatile credit environment. Ewald, who joined Bain Capital in 1998, is a Partner, Global Head of the Private Credit Group, Portfolio Manager for the Middle Market Credit and Senior Direct Lending strategies, and a Credit Committee member. He also serves as CEO of Bain Capital Specialty Finance, a registered business development company. In this conversation, Ewald discusses how Bain is deploying capital amid the volatility driven by President Trump's tariff threats. He explains where he finds opportunities in today's market, what sectors he avoids and his continued focus on the core middle market. The conversation also touches on key shifts in covenant protections and pricing. As syndicated deal flow slows, private credit continues to draw interest.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

What if the best idea for your business isn't coming from your C-suite, but from the intern who barely speaks in meetings? In this episode of The Liquid Lunch Project, hosts Matthew R. Meehan and Luigi “The Professor” Rosabianca sit down with Nick Jain, CEO of IdeaScale, to talk about shaking up the way businesses innovate. Nick drops no-BS insights on how small businesses can harness the power of crowdsourcing ideas, why financial fluency is non-negotiable, and how poker skills can make you a better entrepreneur.    Oh, and he's got a free tool for you small business owners that'll change how you brainstorm—stick around for that.   Episode Highlights: IdeaScale 101: Learn how this “social network for ideas” lets businesses crowdsource game-changing ideas from employees, customers, and beyond. Real-World Win: A global restaurant chain used IdeaScale to crowdsource their next big menu item—and it wasn't just a PR stunt. Big Company vs. Small Company Life: Nick spills the tea on why running a smaller company is like driving a speedboat—faster, riskier, and way more fun. Idea Meritocracy: Why the best ideas should win, not the loudest voice or the highest-paid suit.  Financial Fluency: Nick explains why every entrepreneur needs to master financial statements—or risk driving blind. Poker and Business: How calculated risks at the poker table mirror smart business moves. Free Tool Alert: IdeaScale is free for businesses under 100 people—zero strings attached.  Who is Nick? Nick Jain is the CEO of IdeaScale, a social network for ideas that helps businesses crowdsource innovation. A Harvard Business School grad and former Bain Capital hotshot, Nick's now running a midsize software company while juggling fatherhood, a computer science degree, and fixing electrical outlets at his rental properties.  Take Action: Want to stop chasing your tail and start innovating like a badass? Tune in to hear Nick Jain drop knowledge bombs that'll make you rethink how you run your business. Plus, snag a free tool that'll have your team's best ideas bubbling up faster than a cold beer on a hot day. Listen now—you'll thank us later. Favorite Quote: “If you can't read financial statements, you have no idea how your business is doing. It's like driving with covers on your windshield. You'd never do it.” Connect with Nick: X: https://x.com/NickMJain LinkedIn: https://www.linkedin.com/in/nickjain/ Website: https://ideascale.com   Like what you heard? Don't forget to subscribe, rate, and review!

In this episode of Goldman Sachs Exchanges: Great Investors, Alison Mass, chairman of investment banking in Goldman Sachs Global Banking & Markets, sits down with David Gross, co-managing partner of Bain Capital, to explore the evolving global landscape of private equity and alternative investments. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textOn today's episode, I'm joined by Sandeep Acharya — Founder and CEO of Octave, a company that's quietly but powerfully transforming how we experience mental health care in America. WATCH IT ON YOUTUBE.Under his leadership, Octave has partnered with major insurers to make high-quality, affordable therapy accessible across 23 states. It's been named a LinkedIn Top Startup and one of the best places to work in the country.Before founding Octave, Sandeep wore many hats: investor at Bain Capital and Insight, consultant at Bain & Company, and executive at One Medical, where he helped scale the company nationwide and saw firsthand how deeply unmet our mental health needs are.In this conversation, we go far beyond the bullet points — talking about his battle with cancer, the role of spirituality and music in his life, and what it really takes to build a company that's both mission-driven and sustainable. He shares unfiltered insights on leadership and navigating uncertainty.This one's for the builders, those fighting their own battles, and the believers.South Asian Trailblazers is an award-winning media platform, community, and agency dedicated to elevating leading South Asians. Join our community at SouthAsianTrailblazers.com. Subscribe to our newsletter to get new episodes and updates on our latest events in your inbox. Follow us @southasiantrailblazers on Instagram, LinkedIn, Facebook, Youtube, and all major podcast platforms, including Apple and Spotify.

With tariffs expected on Australian agricultural products, could companies like AACo or Graincorp suffer on the market? MARKET WRAP: ASX200: up 1.04% to 7,925 GOLD: $3,160 US/oz BITCOIN: $133,689 AUD Every sector finished in the green, with Real Estate up by more than 2%. Homebuilder AV Jennings rose by 8.3% to 65 cents after it accepted a $365 million takeover bid from an American real estate company. Goodman gained 2.7%, Stockland rose 2.2% and Charter Hall lifted 3.7% Southern Cross Electrical Engineering sold for $53.5 million, up 9.6%. BHP gained 1.8%, Woodside rose 1.7% and QBE lifted 1.9%. Paladin Energy dropped another 5.7% to $4.82 and is now down more than 26% over the last week Tower fell by 10.4% after Bain Capital sold more than 68 million shares it held in the insurer. Sigma healthcare was more than 1% lower, with James Hardie also falling back by 3.9%. CURRENCY UPDATE: AUD/USD: 62.46 US cents AUD/GBP: 48.4 pence AUD/EUR: 57 Euro cents AUD/JPY: 93 Japanese yen AUD/NZD: 1.10 NZ dollars See omnystudio.com/listener for privacy information.

Dalal Street stays strong as IT stocks lead the gains. Meanwhile, Elon Musk's X challenges India's censorship laws, Bain Capital eyes a major stake in Manappuram Finance, and SEBI's big meeting could shake up foreign investments. Plus, Eli Lilly's weight loss drug enters India, and hospitals shift their focus beyond Bangladesh for medical tourism. Tune in for all the top stories.

Get ready for unfiltered insights on the complexities of impact investing, how government regulations shape the sector, and the balance between profit and purpose-backed by Luca's years of experience with Bain Capital and global leadership roles in companies like Hewlett-Packard, Amcor, and Honeywell.Luca Zerbini, CEO and Co-founder of Una Terra, a €200M VC fund backed by the Prince Albert II of Monaco Foundation, steps into the hot seat to tackle tough questions on impact-driven leadership and sustainability. Marian Temelkov, CEO of Dynamis Group and the host of this podcast- challenging Luca on whether sustainability is truly reshaping the investment landscape or just another trend.Find Luca here!

Welcome to Omni Talk's Retail Daily Minute, sponsored by Mirakl. In today's Retail Daily Minute:Macy's Faces Mixed Earnings Amid Turnaround -- Macy's CEO Tony Spring continues to push forward with the First 50 store upgrades, which have shown stronger performance than the rest of the company. While Macy's exceeded earnings expectations, revenue missed estimates, signaling both progress and ongoing challenges in the retail sector. Google Integrates AI & AR for Smarter Shopping -- Google is enhancing its Shopping tab with Vision Match, a new AI-powered tool that allows users to describe a clothing item, and the system will generate shopping options that match the description. 3️⃣ 7-Eleven's Parent Company Reshapes Strategy -- Seven & i Holdings, the parent company of 7-Eleven, is undergoing a major transformation under its new CEO, Stephen Dacus, who is the first non-Japanese CEO in the company's history. The company has announced a $5.4 billion asset sale to Bain Capital, a move aimed at streamlining its operations and reinforcing its focus on the convenience store segment. Additionally, the company is planning an IPO for its North American operations, signaling an expansion push in the U.S. and Canada. The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights. Be careful out there!

Lucy Coulden currently serves as Global Program Director, Polkadot Ambassador Fellowship, a role commenced in December 2024. Prior to this position, Lucy held the title of Director of Executive Operations at Parity Technologies from March 2022 to March 2024, and previously served as an Executive Assistant to the CEO. Lucy's career also includes significant roles such as C-Suite Executive Assistant at Improbable, Executive Assistant to the Founder CEO at Atomico, and various positions at QuadReal Property Group, Bain Capital, HgCapital, Real Staffing, and Tinies Childcare. With expertise in executive assistance, office management, and recruitment consulting, Lucy has demonstrated a consistent ability to manage complex tasks and support high-level executives across diverse industries. Lucy earned a Bachelor of Arts in History from Queen Mary University of London and possesses a strong educational background in the sciences and humanities.

Lucy Coulden currently serves as Global Program Director, Polkadot Ambassador Fellowship, a role commenced in December 2024. Prior to this position, Lucy held the title of Director of Executive Operations at Parity Technologies from March 2022 to March 2024, and previously served as an Executive Assistant to the CEO. Lucy's career also includes significant roles such as C-Suite Executive Assistant at Improbable, Executive Assistant to the Founder CEO at Atomico, and various positions at QuadReal Property Group, Bain Capital, HgCapital, Real Staffing, and Tinies Childcare. With expertise in executive assistance, office management, and recruitment consulting, Lucy has demonstrated a consistent ability to manage complex tasks and support high-level executives across diverse industries. Lucy earned a Bachelor of Arts in History from Queen Mary University of London and possesses a strong educational background in the sciences and humanities.

Top investor Melissa Bethell drops in to the studio in London to learn the names of countries such as USA, France and China in Chinese. ✨ BIG NEWS ✨ Our brand new Talk Chineasy App, is now live on the App Store! Free to download and perfect for building your speaking confidence from Day 1. portaly.cc/chineasy Visit our website for more info about the app.

En este episodio, analizamos los eventos más relevantes que están afectando los mercados y sectores clave: Wall Street reacciona a la Fed y aranceles de Trump: Los mercados caen ligeramente tras el récord del $SPX, mientras las minutas de la Fed reflejan cautela ante la inflación y políticas comerciales. Analizamos cómo estas preocupaciones están afectando la economía global. Asia en rojo por incertidumbre comercial: Japón y Hong Kong lideran las caídas tras la decisión de Trump de imponer aranceles del 25% a autos, chips y productos farmacéuticos. Exploramos cómo la política arancelaria de EE.UU. está impactando los mercados asiáticos. Microsoft avanza en computación cuántica: $MSFT presenta el Majorana 1, un chip basado en un nuevo estado de la materia, con el potencial de acelerar la computación cuántica en años, no décadas. Analizamos cómo esta tecnología podría transformar la industria y el impacto en acciones de cuántica como $QBTS, $QUBT y $IONQ. KKR adquiere Fuji Soft: La firma de inversión gana la batalla contra Bain Capital y compra el 57.92% de Fuji Soft por $4.4B. Evaluamos cómo esta adquisición busca potenciar la digitalización e IA en Japón. AstraZeneca expande su presencia en China: $AZN adquiere la filial china de FibroGen por $160M, obteniendo los derechos de roxadustat en el país. Discutimos cómo esta transacción impacta la estrategia global de ambas farmacéuticas. Acompáñanos para entender cómo estos eventos están moldeando los mercados, la tecnología y las estrategias corporativas. ¡Un episodio lleno de análisis estratégico!

Angelo Rufino, Partner and Head of Special Situations in North America and Head of Corporate Special Situations in Europe for Bain Capital, joins Bridget Walsh, EY Global Head of Private Equity. In this episode Angelo shares his insights on the differentiated opportunities for Special Situations investing. 17 mins. The views of third parties set out in this podcast are not necessarily the views of the global EY organization or its member firms. Moreover, they should be seen in the context of the time they were made.

米投資ファンドのベインキャピタルは１１日までに、富士ソフトへのＴＯＢについて「撤回することも選択肢に含め、今後の方針を慎重に検討している」との声明を公表した。 U.S. investment fund Bain Capital may not launch a tender offer for Japanese system developer Fuji Soft Inc., it has been learned.

John Rappaport is the Chief Investment Officer at Keyframe Capital, a special situations fund manager. They help management teams solve complex asset and corporate financing requirements. In finance speak, this is often referred to as structured capital—the process of separating a company's capital structure into layers, enabling each layer to be fit for an investor seeking that specific risk-return profile.As John shares, structured capital can often be a good fit for companies in the energy transition, as those in renewable energy and adjacent categories often have high upfront capital costs and a relatively low cost of ongoing production.John has spent much of his career in financial roles within the energy and transportation sectors. Prior to founding Keyframe in 2020, he joined Cyrus Capital Partners in 2008, and before that, he worked for Sankaty Advisors, a division of Bain Capital. He has lectured on structured capital and economics at Yale University and sits on the boards of many companies in the energy transition space, including Wonder Capital, Utility Data, and Sealed, among others.So, let's dive into the wonky but important world of structured capital.In this episode, we cover: [1:57] Overview of Keyframe Capital[2:52] The origin of Keyframe and a story about Terawatt Infrastructure[11:25] Understanding structured capital[17:01] Examples of structured capital: Infrastructure as a service[21:10] Keyframe's thesis-driven approach[25:56] The data center financing challenge[31:02] When and how founders should engage with structured capital providers[35:48] Keyframe's current focus areasEpisode recorded on Jan 21, 2025 (Published on Feb 6, 2025) Enjoyed this episode? Please leave us a review! Share feedback or suggest future topics and guests at info@mcj.vc.Connect with MCJ:Cody Simms on LinkedInVisit mcj.vcSubscribe to the MCJ Newsletter*Editing and post-production work for this episode was provided by The Podcast Consultant

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10  What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.

Creativity through the lens of the CEO of IdeaScale"Taking a solution from another sphere of life and using it in a different space."Nick has lived an inspiring rags to riches story. Nick started his life by being raised by a single grandmother in a small city in India and graduated at the top of his class from Harvard Business School.Along the way, Nick has worked at some of the top investing firms in the world such as Bain Capital and Greenlight, and has led dramatic business transformations in 3 entirely different industries: trucking, men's shoes, and now B2B software.Nick is an expert at marketing, team management, and creating win-win-win outcomes for his 3 stakeholders (customers, employees, shareholders).Nick Jain is the CEO of IdeaScale, the leading innovation software company. IdeaScale is the core of many leading global organization's innovation efforts including NASA, Comcast, NASCAR, Doctors without Borders and many others.Nick graduated at the top of his class from Harvard Business School and holds a degree in mathematics from Dartmouth. He enjoys playing poker, running and travelling with his wife.https://ideascale.com/https://www.linkedin.com/in/nickjain/Send us a text

Ever wonder how tiger moms earned their stripes? In this Talk Chineasy Episode, learn how to say "tiger mom" and "tiger dad" in Chinese as ShaoLan and star investor Melissa Bethell discuss the cultural roots of Chinese "tiger parenting." ✨ BIG NEWS ✨ Our brand new Talk Chineasy App, is now live on the App Store! Free to download and perfect for building your speaking confidence from Day 1. portaly.cc/chineasy Visit our website for more info about the app.

“This Davos is all Trump, all AI,” says Steve Pagliuca, private equity senior advisor at Bain Capital and Boston Celtics co-owner. He discusses his sports teams and NBA viewership, the areas he is most focused on in the development of artificial intelligence, the need to unite rules and regulations within the European Union, and his concerns about inflation and rising interest rates. Pagliuca speaks with Bloomberg's Jonathan Ferro and Lisa Abramowicz at the World Economic Forum's annual meeting in Davos, Switzerland.See omnystudio.com/listener for privacy information.

In this episode of The Deal, Alex Rodriguez and Jason Kelly sit with Steve Pagliuca to discuss his ownership principles for the Boston Celtics and Atalanta Bergamasca Calcio. Pagliuca explains how he ended up with a successful career as an investor at Bain Capital, what lessons he applied to growing sports teams and why he’s proud to be called the Italian Ted Lasso.See omnystudio.com/listener for privacy information.

Nick Jain is the CEO of IdeaScale, the world's largest innovation SaaS company. Raised in India by a single grandmother, he excelled academically, graduating at the top of his class at Harvard Business School and summa cum laude from Dartmouth with a triple major in math, physics, and economics. His career includes leading companies in trucking, men's fashion and software, as well as working at top investment firms like Bain Capital. An evangelist for AI adoption, Nick championed the use of large language models at IdeaScale well before the AI hype cycle began. He pushed for generative AI technologies to be adopted by sales, product designers, and even software engineers, well before such adoption became mainstream. Listen NOW to discover, 3 Ways To Future-Proof Yourself By Leveraging AI

ShaoLan and star investor Melissa Bethell reveal how to refer to a boss in Chinese. Find out why the literal translation of boss, "old plank" is not as insulting as the direct translation would have you believe! ✨ BIG NEWS ✨ Our brand new Talk Chineasy App, is now live on the App Store! Free to download and perfect for building your speaking confidence from Day 1. portaly.cc/chineasy Visit our website for more info about the app.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28  Bausch + Lomb acquires Elios Vision 2:07  ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00  Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31  Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

Today's show is our third in the Training Grounds mini-series, following Carnegie Corporation and Bain Capital to better understand how certain organizations have developed industry leaders. Wellington Management is one of the world's largest, privately held asset managers, managing over $1.3 trillion in assets with 875 investment professionals across 19 offices and a nearly 100 year history with an unusually low level of turnover along the way. Wellington has developed, recruited, and retained leading global investment talent across public equities, fixed income, and recently private markets as well. My guest to discuss this training ground is Jean Hynes, CEO of Wellington, who has spent more than thirty years at the firm starting as an administrative assistant. Our conversation covers Wellington's cultural values and boutique investment team model, including apprenticeship for junior talent, recruiting at the mid-level, and promotion all the way to partner. We then discuss Wellington's evolution from a U.S. equity value shop to a global, multi-asset, multi-strategy powerhouse, and Jean's evolution from a portfolio manager to CEO.   Take Capital Allocators Audience Engagement Survey Learn More Follow Ted on Twitter at @tseides or LinkedIn Subscribe to the mailing list Access Transcript with Premium Membership

In this special crossover episode, Eyeluminaries hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are joined live by Susan MacDonald, MD, and Cathleen McCabe, MD, at Eyecelerator 2024 in Chicago, IL. Intro :07 Welcome to the Eyeluminaries podcast 3:14 In this episode 5:02 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 5:11 What started you on this journey to do humanitarian work? 5:30 MacDonald discusses the role of parents in defining of happiness. 10:56 Hovanesian discusses the background of his humanitarian work in Armenia. 11:36 What about the funding of these humanitarian projects? 12:50 What are your stories from doing humanitarian work? 14:11 What advice to do you have for physicians who want to get involved in humanitarian work? 18:55 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 22:23 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 22:50 MacDonald discusses how her humanitarian work began. 23:28 Thank you. 27:05 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 27:51 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 28:42 Visit ACE Global, Cybersight or Operation Sight to get involved. 28:54 Mend the Gap podcast 30:49 Preview of episode 30 32:17 Give us your feedback 32:44 Thanks 33:17 Thoughts 33:27 Visit the ASCRS Foundation to get involved in Operation Sight. 34:20 Thank you for listening! 35:17 Don't forget to like and subscribe to Mend the Gap and Eyeluminaries! 35:39 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on X (formerly Twitter) @Healio_OSN. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Private equity firms Blackstone and Bain Capital are close to finalizing a potential $3 billion deal for Mitsubishi's pharma unit, Mitsubishi Tanabe Pharma. In other news, five drugs have been flagged for unjustified price hikes in 2023 by the Institute for Clinical and Economic Review. Incyte and Iteos are cutting drug candidates from their cancer pipelines due to disappointing data, while the FDA advisory committee has called for more research on Moderna's RSV vaccine after safety issues arose. Layoffs have been announced at Intercept and Editas, and there has been a slowdown in M&A activity in the pharma industry this year. US Pharmacopeia is looking for expert volunteers to work on medicine quality challenges.

“A marriage…chemistry… [and] shared vision” is how Bain Capital partner Angelo Rufino described investments centered around a new asset class of hybrid capital that combines features of debt and equity in a conversation with Bloomberg Intelligence's Negisa Balluku that took place live at Beard Group's Distressed Investing Conference. As Head of Special Situations in North America as well as Head of Corporate Special Situations in Europe, Rufino shared his perspective on the bespoke nature and the “win-win” value proposition of a special situations product that provides both operational value-add and financing capital. (8:36) Prior to that, Noel Hebert, head of Bloomberg Intelligence's global credit strategy, and Philip Brendel, BI distressed-credit analyst, assessed the impact of an improved M&A environment in a Trump administration on distressed-debt supply. The podcast concludes with Negisa, Phil and Noel discussing the latest developments in Spirit Airlines, J&J's talc bankruptcy, Yellow, Hertz, Avon and Hearthside. (52:27)

It's almost Thanksgiving! Mitch Frazier and Cayla Chiddister sit down to recap November and get into: - The election's impact on farmers and agbioscience innovation.- Creating certainty for farmers in this new environment to plan for their operations.- Bain Capital investment into a merger of Biodyne USA, BW Fusion and Agronomy 365.- Entrepreneurship Week in Indiana.- Quadrant coming up on December 4!- Announcing a winner of the 2024 Producer-Led Innovation Challenge.

It's almost Thanksgiving! Mitch Frazier and Cayla Chiddister sit down to recap November and get into: - The election's impact on farmers and agbioscience innovation.- Creating certainty for farmers in this new environment to plan for their operations.- Bain Capital investment into a merger of Biodyne USA, BW Fusion and Agronomy 365.- Entrepreneurship Week in Indiana.- Quadrant coming up on December 4!- Announcing a winner of the 2024 Producer-Led Innovation Challenge.

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work. Welcome to the Eyeluminaries podcast :02 In this episode :31 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00 What started you on this journey to do humanitarian work? 2:18 MacDonald discusses the role of parents in defining of happiness. 7:47 Hovanesian discusses the background of his humanitarian work in Armenia. 8:24 What about the funding of these humanitarian projects? 9:38 What are your stories from doing humanitarian work? 10:59 What advice to do you have for physicians who want to get involved in humanitarian work? 15:43 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 19:11 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 19:38 MacDonald discusses how her humanitarian work began. 20:16 Thank you. 23:49 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30 Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38 Mend the Gap podcast 27:37 Preview of episode 30 29:05 Give us your feedback 29:25 Thanks 30:05 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

Romney's Bain Capital helped dismantle left-wing talk network Air America. Will something similar happen to MSNBC? Republicans are gunning for Republicans. Will their be anything left beside subsidized right-wing propaganda?Plus- Thom reads from "How Wealth Rules the World: Saving Our Communities and Freedoms from the Dictatorship of Property" by Ben G. Price. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“Good innovation happens iteratively, not with a splash and bang.”Nick Jain Top Five Tips For Innovating In Large Organizations1.      Focus on running small experiments and collecting data2.      Ensure your innovation efforts align with your organization's objectives3.      Create cross-functional teams4.      Create a culture and incentive structure that encourages innovation5.      Provide the right tools and technology to enable innovation. TIME STAMP SUMMARY02:18 Importance of a good approach vs a big risky initiative 06:26 Innovative efforts linked to the company's core priorities and goals11:53 The 4G Framework of Incentives1640: Providing the right tools and technology is a crucial part in innovation Where to find Nick Website                          https://ideascale.com/ LinkedIn                         https://www.linkedin.com/in/nickjain/  Nick Jain Bio Nick Jain is the CEO of IdeaScale, the world's largest innovation SaaS company. Known for his commitment to high-quality products, he has dramatically reduced software bugs and boosted customer satisfaction.Nick's journey is one of resilience. Raised in India by a single grandmother, he excelled academically, graduating at the top of his class at Harvard Business School and summa cum laude from Dartmouth with a triple major in math, physics, and economics. His career includes leading companies in trucking, men's fashion and software, as well as working at top investment firms like Bain Capital.An evangelist for AI adoption, Nick championed the use of large language models at IdeaScale well before the AI hype cycle began. He pushed for generative AI technologies to be adopted by sales, product designers, and even software engineers, well before such adoption became mainstream.Outside of work, Nick enjoys poker, running, listening to battle rap, and traveling. He's also an avid reader, currently tackling “Moby Dick” and the fantasy novel “Lyorn.”

 Is It Time To Upgrade Your Tax Team?  Forward Thinking Tax Strategies  Ready to unlock the tax secrets that could save you thousands and accelerate your business growth? Join Marcia Riner and tax expert David Snider, CEO of Harness Wealth, as they dive into tax strategies that go beyond mere compliance. Think your current tax team has your back? Think again. From choosing the right business structure to discovering little-known tax incentives, David sheds light on ways your tax strategy might be holding your business back. Whether you're planning to expand, acquire, or even sell, this episode will open your eyes to how proactive tax planning can be a powerful growth engine. It's time to think forward and ask: Do you have the right tax team to get you there? Key Talking Points & Timestamps [00:02:05] Meet David Snider David's impressive journey from Bain Capital to founding Harness Wealth. How his experiences drive his mission to make tax and financial guidance accessible. [00:03:30] Business Structuring for Tax Optimization Understanding the impact of business structure on taxes, from QSBS benefits to choosing the right entity. [00:06:40] Differences Between Tax Planning & Compliance David outlines the proactive nature of tax planning vs. typical compliance, emphasizing the value of ongoing advisory. [00:09:15] Real-Time Tax Strategy How “safe harbor” rules, estimated taxes, and cash flow timing can protect your business from unexpected liabilities. [00:12:40] Entity Choice & Tax Advantages Post-2017 Tax Cuts implications and benefits of alternative structures like multi-member LLCs and S-Corps for reducing state taxes. [00:16:55] Proactive Tax Advisory for Business Growth The importance of having a tax advisor who's actively monitoring your business goals, potential industry changes, and tax policy shifts. [00:22:25] Leveraging Tax Advisors as Strategic Growth Partners From R&D credits to location-based incentives, David discusses the tax tools that can significantly lower operational costs for growth. [00:25:30] Specialized Advisory for Niche Markets Why niche-focused tax advisors, who understand the unique needs of your industry, can boost growth faster than a generalized approach. [00:27:40] Outsourced CFO Services When and how businesses can benefit from outsourced CFO support as part of their tax advisory for financial forecasting and strategic cash flow management. Conclusion: If you're still wondering whether your current tax team has what it takes to drive your business forward, this episode is your wake-up call! David Snider reveals the possibilities that come with having a proactive, forward-thinking tax advisor in your corner—someone who can help you navigate tax policies, optimize cash flow, and fuel your company's growth goals. With the right tax team, you're not just saving money—you're setting your business up for lasting success. Take advantage of David's exclusive offer and get a complimentary consultation at https://harnesswealth.com/Marcia. Remember, the best investment you can make is in a tax strategy that aligns with your vision for growth!   Subscribe & Learn More: Don't miss future episodes of Profit with a Plan, where we share tips and strategies to grow your business and increase profitability. Subscribe on your favorite podcast platform      These notes are optimized for keywords such as Forward-thinking tax strategies, Business tax planning, Outsourced CFO for small business growth, Optimize taxes for business growth and Tax team for business sale planning.     This episode is sponsored by Infinite Profit ® —We don't just talk profit — we deliver it! Is your business ready for explosive growth? Visit InfiniteProfitConsulting.com to learn how Marcia and her team can help you boost profits and set your business up for long-term success.     Grab Your Free Resource: Looking to supercharge your profits? Download Marcia's Profit Booster Playbook at BoostingProfit.com to uncover three essential strategies to increase your bottom line today.     About Marcia Riner.  She is a business growth strategist who helps business owners dramatically increase their revenue, profit, and the value of their company. In fact, she can show prospective clients a clear pathway to profit and an impactful ROI for working here before hiring her firm. Through her proven Profit Booster® strategies, she gets results. Marcia is the CEO of Infinite Profit® and more information can be found at https://www.InfiniteProfitConsulting.com Got questions?  Reach out to Marcia and her team at (949) 229-2112 ♾️

102524 2nd HR Really Graceful Her Visit To NC WOW And Deep Dive BAIN Capital And Pdiddy by Kate Dalley

In part two of our interview series, we explore how private equity can continue expanding its global footprint and what it will take to thrive in a multipolar world.

The co-managing partner of Bain Capital takes us inside of their remarkably diversified portfolio, where venture capital, private equity, real estate, and credit don't just coexist—they actively reinforce each other.If you'd like to stay up to date with my weekly series of posts on LinkedIn, you can follow me here.

Send us a textWe've talked a lot about how Private Equity Megafunds approach valuation when they purchase companies through LBOs. And we've spoken about their exits, either through IPOs or PE Secondaries.  But we've never really talked about what happens during the YEARS in between!  How do Private Equity companies actually grow their portfolio companies over the life of their investment? Enter: the operations team. This group works closely with executives at the portfolio company itself, along with the valuation and deal teams. This team is generally separate from the deal team within Megafunds, though many roles may have significant overlap at smaller firms. At a Megafund, this role differs considerably in terms of skills set, background, and career path. Instead of a conveyor belt path through Investment Banking, this group looks for for skilled consultants and experienced corporate executives. It can be a fantastic entry point into Private Equity for older candidates with more experience in the workforce.Today, we sit down with Florence Evina-Ze, an SVP at Bain Capital, to discuss the recruiting, career path, skills set, and lifestyle associated with this particular vertical. Florence also shares her perspective as an underrepresented minority in the industry. She discusses specific programs that were instrumental to her success, the critical role of mentors, and her inspiring approach to helping others follow in her footsteps.Florence Evina-Ze joined Bain Capital in 2021. She is a Senior Vice President in the Portfolio Group and a member of the North America Private Equity team. Prior to joining Bain Capital, Florence worked at IPSY. Previously, she was a consultant at McKinsey and Deloitte where she focused on industrials and consumer/retail. Florence earned an MBA from Harvard Business School and SB in mechanical engineering from Harvard College.Check out Public.com at the link http://public.com/wallstreetskinnyJoin the waitlist for our flagship course on IB and PE fundamentals!https://the-wall-street-skinny.mykajabi.com/waitlist-opt-in-IBDPublic Disclosure: All investing involves risk. Brokerage services for US listed securities, options and bonds in a self-directed brokerage account are offered by Public Investing, member FINRA & SIPC. Not investment advice. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank.Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1828849), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. Securities investments: Not FDIC Insured; No Bank Guarantee; May Lose Value. See public.com/#disclosures-main for more information.Our content is for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice.

090424 SHORT 2 MIN Interesting Bain Capital Buyout Recently by Kate Dalley

In this episode, Scott Becker discusses the major moves in healthcare by large private equity funds, including the Carlyle Group’s bid for Baxter’s kidney care unit and Bain Capital’s significant investment in India. He also highlights the importance of leadership transitions with insights on the Chipotle CEO’s shift to Starbucks.